Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
AEON Biopharma, Inc.
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05016661CT.gov Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention | — | Terminated | — | — | — |
NCT04845178CT.gov Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prabotulinumtoxina Xvfs (this asset) | AEON Biopharma, Inc. | P2 | CCC · 52 |
| Atogepant | Stanford University | P4 | A |
| Zolmitriptan | Zosano Pharma Corporation | P4 | A |
| Rizatriptan | Antonios Likourezos | P4 | A |
| Naproxen | IRCCS San Raffaele Roma | P4 | A |
| Dfn-11 (Sumatriptan Injection) | IRCCS San Raffaele Roma | P4 | BBB |
| Ubrogepant | H. Lundbeck A/S | P4 | BBB |
| Eptinezumab | Stanford University | P4 | BBB |
| Galcanezumab | Stanford University | P4 | BBB |
+42 more in the Migraine Disorder cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prabotulinumtoxina Xvfs in Migraine Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prabotulinumtoxina-xvfs-migraine-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →